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Edited by Hans EklundAbstract 5-Aminolevulinic acid synthase-1 (ALAS1) and heme
oxygenase-1 (HO-1) are the rate-controlling enzymes for heme
biosynthesis and degradation, respectively. Expression of these
two genes showed tissue-speciﬁc expression pattern at both
mRNA and protein levels in selected non-treated rat tissues. In
the livers of rats receiving oral ethanol for 10 weeks, ALAS1
mRNA levels were increased by 65%, and the precursor and ma-
ture ALAS1 protein levels were increased by 1.8- and 2.3-fold,
respectively, while no changes were observed in HO-1 mRNA
and protein levels, compared with pair-fed controls. These results
provide novel insights into the eﬀects of chronic ethanol con-
sumption on hepatic heme biosynthesis and porphyrias.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: 5-Aminolevulinic acid synthase-1 (ALAS1); Heme
oxygenase-1 (HO-1); Ethanol; Gene expression; Porphyria;
Rat liver1. Introduction
5-Aminolevulinic acid synthase-1 (ALAS1) is the ﬁrst and
normally rate-controlling enzyme of hepatic heme synthesis
and is the house keeping form of ALA synthase [1–4].
5-Aminolevulinic acid synthase 2 (ALAS2) is another isoform
of ALA synthase, which is expressed virtually only in develop-
ing red blood cells [3,5]. Both ALAS1 and ALAS2 use glycine
and succinyl-CoA as substrates and are synthesized in the
rough endoplasmic reticulum (ER) as precursor proteins. Both
isoforms, however, are believed to function only in mitochon-
dria, the site of succinyl-CoA synthesis. Thus, like other nucle-Abbreviations: ALAS1, 5-aminolevulinic acid synthase-1; ALAS2, 5-
aminolevulinic acid synthase 2; ER, endoplasmic reticulum; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; HO-1, heme oxygenase-1;
LDC, Lieber-DeCarli; PCR, polymerase chain reaction; qRT-PCR,
quantitative real-time PCR; SDS–PAGE, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis
*Corresponding author. Address: Liver-Biliary-Pancreatic Center,
Carolinas Medical Center, 1000 Blythe Boulevard, Charlotte, NC
28203, United States. Fax: +1 704 355 7648.
E-mail address: jianyu.zheng@carolinashealthcare.org (J. Zheng).
0014-5793/$34.00  2008 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2008.04.047ar-encoded mitochondrial proteins, ALAS1 and ALAS2 must
be transported into mitochondria, with cleavage of a leader
sequence [6]. In contrast to ALAS2, which is not responsive
to chemicals or drugs, ALAS1 is up-regulated by chemicals
and drugs [7–9]. Heme oxygenase-1 (HO-1), the rate-control-
ling enzyme for heme degradation, is the inducible form of
heme oxygenase. Induction of HO-1 serves as an adaptive re-
sponse to protect cells from oxidative stress and other types
of stress through breakdown of unassigned heme to biliverdin,
bilirubin, and carbon monoxide [10,11].
Studies suggest that a single ALAS1 mRNA is expressed in
all rat tissues; however, the expression levels in each tissue
measured by diﬀerent groups remain controversial [12,13].
Additionally, it is not clear whether there is a correlation or
correspondence between levels of expression of ALAS1
mRNA and those of ALAS1 protein in particular tissues and
organs. The same is true of HO-1 mRNA and protein.
Earlier work showed that ethanol administration increases
hepatic ALAS1 enzyme activities in rats [14–16]. Some have
proposed that this eﬀect is secondary to depletion of a heme
regulatory pool, which is depleted during increased formation
of cytochrome(s) P-450 [15]. In rat hepatocyte cultures, the
addition of 16 mM ethanol for 24 h, causes a three-fold in-
crease in the activity of ALAS1 [17]. In humans, increased
ALAS1 activity may lead to the accumulation of neuro- and
dermato-toxic intermediates of the heme biosynthetic path-
way, such as may occur in the porphyrias [1,18–20]. Thus,
ingestion of alcoholic beverages may trigger or exacerbate
acute porphyric attacks. It is critical to understand how etha-
nol exerts its eﬀects on inducing hepatic ALAS1 enzyme activ-
ity.
In the present study, the questions of: (1) tissue-speciﬁc
expression of ALAS1 and HO-1 mRNA and protein levels in
selected non-treated rat tissues, and (2) eﬀects of chronic etha-
nol administration on ALAS1 and HO-1 mRNA and protein
levels in rat liver were investigated by quantitative real-time
polymerase chain reaction (PCR) and Western blotting analy-
sis. We show that the expression of both ALAS1 and HO-1 is
tissue-speciﬁc, and there is a correspondence between levels of
HO-1 mRNA and protein, but not between those of ALAS1
mRNA and protein. Chronic ethanol feeding induces ALAS1
mRNA, cytosolic ALAS1 and mature ALAS1 protein levels,
but not those of HO-1 in rat livers. These provide further evi-
dence for alcohol consumption as trigger of acute porphyric
attacks in human.ation of European Biochemical Societies.
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2.1. Materials
Lieber-DeCarli (LDC) liquid diet was purchased from Dyets Inc.
(Bethlehem, PA). All the reagents for reverse transcription and quan-
titative real-time PCR (qRT-PCR) were purchased from Sigma (St.
Louis, MO). Rabbit anti-human ALAS1 antibody was supplied by Ab-
cam (Cambridge, MA). Rabbit anti-human HO-1 polyclonal antibody
was from StressGen (Victoria, BC, Canada). Goat anti-GAPDH anti-
body was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
ECL-Plus was from Amersham Biosciences Corp. (Piscataway, NJ).
Ponceau S was from Sigma (St. Louis, MO).
2.2. Animal model of chronic ethanol feeding
All experimental procedures were approved by the Institutional Ani-
mal Care and Use Committee and performed in accordance with the
National Institutes of Health criteria for care and use of laboratory
animals. Untreated male Sprague–Dawley rats (250–300 g; Charles
River Laboratories, Wilmington, MA) were anesthetized with xylazine
(3 mg/kg) and ketamine (70 mg/kg), and livers, forebrains, kidneys,
lungs, spleens, recturs abdominis and hearts were rapidly resected,
snap-frozen in liquid nitrogen, and stored at 80 C.
Chronic ethanol administration was described previously [21]. Male
Sprague–Dawley rats as described above were randomly assigned to
experimental groups, and fed either control or ethanol-containing
LDC liquid diet for 10 weeks. In ethanol feeding groups, the amount
of ethanol in the LDC was sequentially increased during the ﬁrst week
of feeding until the amount of ethanol in the diet comprised 36% of to-
tal dietary calories. In subsequent weeks, the amount of food provided
was altered according to consumption and adjusted for changes in
body weight. Control groups received an isocaloric liquid diet in which
maltodextrins were substituted isocalorically for ethanol. During the
course of the studies, food intakes were measured daily, body weights
were measured weekly, and animals were allowed free access to drink-
ing water. During euthanasia, livers were rapidly resected, snap-frozen
in liquid nitrogen, and stored at 80 C for RNA and protein analysis.
2.3. RNA preparation and quantitative real-time PCR
Total RNA isolation, reverse transcription and qRT-PCR were per-
formed as previously described [22]. Brieﬂy, total RNA was isolated
from frozen liver tissue (approximately 50 lg) using TRIzol (Invitro-
gen). For reverse transcription, 1 lg of total RNA was used with the
following speciﬁc primers for qRT-PCR. The ALAS1 sense primer
was 5 0-GGC AGC ACA GAT GAA TCA GAG AG-3 0, and the
ALAS1 antisense primer was 5 0-TTC AGC AAC CTC TTT CCT
CAC GG-3 0. In order to conﬁrm the speciﬁcity of qRT-PCR, samples
without template or without reverse transcriptase were used as nega-
tive controls. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as an invariant internal control for liver samples. The sense
primer for GAPDH was 5 0-TTG TTG CCA TCA ATG ACC C-3 0
and the antisense primer for GAPDH was 5 0-CTT CCC GTT
CTC AGC CTT G-3 0. Primers for HO-1 were as described previously
[22].
2.4. Western blots
Western blotting analysis was as described previously [23]. Liver
samples were homogenized in lysis buﬀer (150 mM sodium chloride,
50 mM Tris–HCL, pH 7.2 and 5% Nonidet P-40) with protease inhib-
itor cocktail from Pierce (Rockford, IL). Thirty-ﬁve to seventy-ﬁve
micrograms of protein were separated on 7.5% sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE) from Bio-Rad
(Hercules, CA). After electrophoretic transfer onto Immun-Blot poly-
vinylidene ﬂuoride membranes (Bio-Rad), the membranes were
blocked with 5% non-fat dry milk in phosphate-buﬀered saline with
Tween-20 (0.1% Tween-20) for 1 h, and then incubated with primary
antibody for 1 h at room temperature. The dilutions of the primary
antibodies were 1:5000 for anti-ALAS1 antibody, 1:2000 for anti-
HO-1 antibody, and 1:1000 for anti-GAPDH antibody. The mem-
branes were then incubated for 1 h with horseradish peroxidase-conju-
gated secondary antibodies (dilution 1:10000). Finally, the bound
antibodies were visualized with the ECL-Plus chemiluminescence sys-
tem, according to the manufacturers protocol (Amersham, Piscata-
way, NJ). A Kodak 1DV3.6 computer-based imaging system
(Eastman-Kodak, Rochester, NY) was used to measure the relativeoptical density of each speciﬁc band obtained after Western blotting.
Data are expressed as percentage of the control.
2.5. Statistical analysis
All experiments included at least triplicate samples for each treat-
ment group. Experiments were repeated at least three times with sim-
ilar results. Representative results from a single experiment are
presented. Statistical analyses were performed with JMP 4.0.4 software
(SAS Institute, Cary, NC). Initial descriptive statistics showed that the
results for continuous variables were distributed normally. Therefore,
the diﬀerences in mean values were assessed by ANOVA, with the Tu-
key–Kramer correction for multiple pair-wise comparisons, or Dun-
netts test versus a control. Values of P < 0.05 were considered
signiﬁcant.3. Results and discussion
3.1. Determination of ALAS1 and HO-1 mRNA levels in
selected rat tissues
In order to determine ALAS1 mRNA levels, seven tissues,
including liver, forebrain, kidney, spleen, lung, abdominal
skeletal muscle and heart were collected. Total RNA was iso-
lated and ALAS1 mRNA levels were determined by qRT-
PCR. As shown in Fig. 1A, ALAS1 mRNA levels (relative
to 28S ribosomal RNA) were set as 1 in the liver, and were
compared to this level in other tissues. The relative levels of
ALAS1 mRNA were about 40% those of liver in the forebrain,
kidney and heart, and were less than 20% in the lung, spleen
and muscle. These results diﬀer slightly from those published
previously [13] in which the levels of ALAS1 in lung, heart
and muscle were similar or higher than those in the liver. These
diﬀerences may indicate age or measuring technique variations
since tissues from rats of 250–300 g body mass were collected
followed by qRT-PCR in this study, while those from rats of
100 g body mass were collected followed by Northern blot
and densitometric scanning in the previous study. The low
ALAS1 levels in the muscle observed in this study might be
due to the speciﬁc abdominal skeletal muscle being utilized.
In comparison to ALAS1, mRNA levels of another key en-
zyme in the heme metabolic pathway, namely, heme oxygen-
ase-1 (HO-1), the rate-controlling enzyme for heme
breakdown, were also determined. As shown in Fig. 1B, by
far, the highest expression of HO-1 mRNA levels were ob-
served in the spleen: 6.6-fold of those in the liver. This agrees
well with the known roles of the spleen to engulf and digest
senescent erythrocytes. In forebrain, HO-1 mRNA levels were
66% of those in liver, whereas, they were nearly undetectable in
other tissues tested.
When measuring mRNA levels in cell cultures, we and oth-
ers usually ‘‘normalize’’ ALAS1 or HO-1 mRNA levels to
those of ‘‘house keeping genes’’, such as GAPDH or 18S ribo-
somal RNA (rRNA). However, in rat tissues, these house
keeping genes were expressed at diﬀerent levels among tissues.
For example, in forebrain, GAPDH mRNA levels were 3.3-
fold of those in the liver, but were nearly undetectable in the
lung and abdominal skeletal muscle (Supplementary Figure
1). For 18S rRNA, in the kidney, spleen and heart, the mRNA
levels were only about 20% of those in the liver (data not
shown). We therefore, determined the quality and quantity
of total RNA (represented by 28S rRNA in Fig. 1C) from each
tissue by electrophoretic analysis, and found that total RNA
from all tissues studied was of good quality and similar quan-
tity.
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Fig. 1. Relative expression of ALAS1 (A) and HO-1 (B) mRNA in selected rat tissues. Seven tissues were collected from each of three control rats.
Total RNA was isolated from each tissue by TRIzol. ALAS1 (A) and HO-1 (B) mRNA levels were determined by qRT-PCR. To conﬁrm the quality
and quantity of total RNA, 1 lg RNA from each tissue was loaded on 1% ethidium bromide agarose gel. The top band corresponding to the 28S
ribosomal RNA is shown (C). Data in (A) and (B) represent means ± S.D., n = 3, normalized to the level of 28S ribosomal RNA of the respective
tissue in (C). Liver ALAS1 (A) and HO-1 (B) mRNA levels are set to 1, and mRNA levels from other tissues are normalized to those in the liver.
Brain represents the forebrain; muscle represents the abdominal skeletal muscle.
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lism. Expression of these genes at mRNA levels, however, is
distinct among tissues. Interestingly, in the forebrain, ALAS1
and HO-1 mRNA expressions were about 40% and 60%,
respectively, of those found in the liver (Fig. 1A and B), sug-
gesting they are important for adult brain. Several recent lines
of evidence suggest that heme deﬁciency might lead to neuro-
nal dysfunction and aging [24,25]; it will be important to inves-
tigate further how ALAS1 and HO-1 are expressed and
regulated in the brains of animals as they age.
3.2. Determination of ALAS1 and HO-1 protein levels in
selected rat tissues
As shown in Fig. 2A, ALAS1 protein levels were greater in
the liver, lung, spleen and heart than those in the forebrain,
kidney and abdominal skeletal muscle. The relative protein
levels are quantitated and shown as a bar graph in Fig. 2D.
The same blot was reprobed with anti-HO-1 antibody, and is
shown in Fig. 2B. HO-1 was the highest in the spleen, slightly
detectable in the abdominal skeletal muscle, and almost unde-tectable in other tissues. Since GAPDH protein levels diﬀered
among the seven tissues tested (Supplementary Figure 2), to
conﬁrm the equal loading, the same membrane was stained
with Ponceau (Fig. 2C). We found that although there was
no single band that consistently appeared among all these tis-
sues, it is reasonable to consider that the loadings are equal
among diﬀerent lanes (tissues), based on the total intensities
of the bands on each lane.
Although ALAS1 mRNA levels in the forebrain, kidney and
heart were about 40% of those in the liver (Fig. 1A), ALAS1
protein levels were less than 40% in the forebrain and kidney,
but about 40% higher in the heart than those in the liver (Fig.
2D). On the other hand, ALAS1 mRNA levels were less than
20% in the spleen and lung, however, ALAS1 protein levels
were similar or higher (two-fold) in spleen and lung than those
in the liver. To further compare the expression level of protein
versus mRNA in each tissue, the ratio(s) of ALAS1 protein/
mRNA was calculated as shown in Fig. 2E. The ratio of
ALAS1 protein/mRNA was 15 in the lung and spleen, and
was about 40 in the heart, whereas, it was similar in the
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Fig. 2. Western blot analysis of ALAS1 and HO-1 protein levels in selected rat tissues. Seven tissues were collected from each of three control rats,
homogenized, and 35 lg of proteins were separated on 7.5% SDS–PAGE, transferred to a polyvinylidene ﬂuoride membrane, and probed with anti-
ALAS1 antibody (1:5000 dilution) (A) and anti-HO-1 antibody (1:2000 dilution) (B). Equal loading of total protein from each tissue was conﬁrmed
by Ponceau S staining of the polyvinylidene ﬂuoride membrane after gel transfer and before Western blot (C). Representative results from one of the
three rats are shown in (A)–(C). ALAS1 protein levels were quantitated from each of the three rats and the average level is shown as a bar graph in
(D). The ratio of ALAS1 protein and RNA levels calculated based on this ﬁgure (D) and Fig. 1A is shown as a bar graph in (E). Brain represents the
forebrain; muscle represents the abdominal skeletal muscle.
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that in the liver. These results suggest a single ALAS1 mRNA
molecule is subject to diﬀerential regulatory mechanism in
translation into its protein in distinct tissues. Due to the low
expression of HO-1 protein in many tissues, we did not per-
form similar calculations for HO-1. However, it is reasonable
to speculate that although there is tissue-speciﬁc expression
at both mRNA and protein levels, the ratio(s) of HO-1 pro-
tein/mRNA was similar among diﬀerent tissues tested.3.3. Eﬀects of chronic ethanol administration on ALAS1 and
HO-1 mRNA levels
As shown in Fig. 3A, hepatic ALAS1 mRNA levels were sig-
niﬁcantly increased (+65%) after ethanol administration for 10
weeks, compared with the pair-fed control (P < 0.05). On the
other hand, no signiﬁcant changes were observed in HO-1
mRNA levels between ethanol treated and pair-fed control
(Fig. 3B). We also measured GAPDH mRNA levels in ethanol
administrated livers and pair-fed controls. As shown in Fig.
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Fig. 3. Eﬀects of chronic administration of ethanol on rat liver ALAS1 and HO-1 mRNA levels. Rats were administrated ethanol or isocalorically
substituted maltodextrins for 10 weeks. Total RNA was isolated from livers of each of three rats. ALAS1 (A) and HO-1 (B) mRNA levels were
determined by qRT-PCR, and normalized to an invariant GAPDH control (C). Data represent means ± S.D. for each group of three rats with
triplicates of each rat. *Diﬀers from control, P < 0.05.
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Fig. 4. Eﬀects of chronic administration of ethanol on rat liver ALAS1
protein levels. Rats were administrated ethanol or isocalorically
substituted maltodextrins for 10 weeks, as described in Section 2.
Livers were harvested, frozen, homogenized, and subject to SDS–
PAGE and Western blotting analysis, as described in Fig. 2. The
ALAS1 antibody detected two bands: higher molecular weight (high
MW) and lower molecular weight (low MW) bands of  71, and
65 kDa, respectively (Panel A). Intensity of staining of each band was
quantiﬁed and normalized to the GAPDH control as shown in the bar
graph (Panel B). Data represent means ± S.D. for each group of three
rats. *Diﬀers from control, P < 0.05. In (A) ‘‘C’’ and ‘‘E’’ represent
control and ethanol, respectively. In (B) ‘‘a’’ and ‘‘b’’ represent high
MW and low MW band, respectively.
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gene) of qRT-PCR, suggesting ethanol had no eﬀects on the li-
ver GAPDH mRNA levels. Therefore, in Fig. 3A and B,
ALAS1 and HO-1 mRNA levels were normalized to GAPDH
mRNA levels. These results suggest that ethanol speciﬁcally in-
duces ALAS1 mRNA levels, although it is not clear whether
this induction is through an enhanced transcription and/or
an increase in mRNA stability. Further studies will be needed
to address this issue.
3.4. Eﬀects of chronic ethanol administration on ALAS1 protein
levels
To further determine the eﬀects of chronic ethanol adminis-
tration on ALAS1 gene expression, ALAS1 protein levels were
determined by Western blotting analysis. As shown in Fig. 4A,
the anti-ALAS1 antibody detected two bands, which may cor-
respond to the precursor form (higher MW, 71 kDa), and the
mature form (lower MW, 65 kDa). Ethanol treatment in-
creased the levels of both forms, especially the 65 kDa form.
Since ethanol had no eﬀect on liver GAPDH protein levels
(Fig. 4A, bottom panel), ALAS1 protein levels were quanti-
tated and normalized to GAPDH control (Fig. 4B). In Fig.
4B, without ethanol treatment, the lower molecular weight
(MW) form was 44% of the higher form. After ethanol treat-
ment, both forms increased signiﬁcantly: the higher MW form
increased by 1.8-fold (P < 0.05), while the lower form in-
creased by 2.3-fold (P < 0.05). These results suggest that
chronic ethanol administration induces both the precursor
and mature forms of ALAS1 and has a relatively greater eﬀect
on the formation of mature form. Using these same sets of ani-
mals in another independent experiment, we found that cyto-
1834 J. Zheng et al. / FEBS Letters 582 (2008) 1829–1834chrome P450 2E1, an inducible marker for ethanol treatment
was signiﬁcantly increased [21]. Our ﬁndings agree well with
the previously published results in which chronic ethanol
administration increased hepatic ALAS1 enzyme activities by
two- to three-fold compared with those pair-fed controls [14–
16]. Considering that the intra-mitochondrial mature ALAS1
is the functional form, and 2.3-fold increase in the levels of
the mature protein after ethanol treatment provides a rationale
for the ethanol induced increase (two- to three-fold) in ALAS1
enzyme activities observed by other investigators [14–16]. In
this same experiment, HO-1 protein levels were nearly unde-
tectable (data not shown), suggesting ethanol had no eﬀect
on HO-1 protein levels.
Abundant evidence from animal and cell culture models
indicates that ethanol induces hepatic ALAS1 enzyme activi-
ties. Results from this study suggest that ethanol induces
ALAS1 gene expression at the level of transcription, transla-
tion, and also exerts post-translational regulation (precursor
processing) in the livers of rats. Our ﬁnding that chronic etha-
nol treatment induces ALAS1 but not HO-1 gene expression
provides further understanding of ethanol as a trigger of acute
porphyric attacks.
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